Final survival and safety results from a multicenter, open‐label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer
DR Spigel, M Lin, V O'Neill… - … International Journal of …, 2008 - Wiley Online Library
BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy …
FA Shepherd, J Pereira, TE Ciuleanu… - Journal of Clinical …, 2004 - ascopubs.org
7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer
N Sheikh, CR Chambers - Journal of Oncology Pharmacy …, 2013 - journals.sagepub.com
Background: A randomized trial carried out by Shepherd et al. in patients with advanced or
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …
[HTML][HTML] Erlotinib in previously treated non–small-cell lung cancer
FA Shepherd, J Rodrigues Pereira… - New England journal …, 2005 - Mass Medical Soc
Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study
DF Heigener, YL Wu, N van Zandwijk, P Mali… - Lung Cancer, 2011 - Elsevier
Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …
Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials
H Gao, X Ding, D Wei, P Cheng, X Su, H Liu… - Anti-Cancer …, 2011 - journals.lww.com
Erlotinib is a potent reversible HER1/epidermal growth factor receptor tyrosine kinase
inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this …
inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this …
A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer
G Giaccone, T Lechevalier, N Thatcher… - Journal of Clinical …, 2005 - ascopubs.org
7073 Background: Erlotinib (TarcevaTM) is an orally available selective EGFR tyrosine-
kinase inhibitor. In patients with advanced NSCLC, 2nd/3rd-line erlotinib significantly …
kinase inhibitor. In patients with advanced NSCLC, 2nd/3rd-line erlotinib significantly …
Erlotinib for frontline treatment of advanced non–small cell lung cancer: a phase II study
G Giaccone, M Gallegos Ruiz, T Le Chevalier… - Clinical Cancer …, 2006 - AACR
Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
Erlotinib: as maintenance monotherapy in non-small-cell lung cancer
VJ Muir, S Dhillon - BioDrugs, 2011 - Springer
Erlotinib is a low molecular weight, orally active, epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor. Inhibition of EGFR tyrosine kinase results in the disruption of …
tyrosine kinase inhibitor. Inhibition of EGFR tyrosine kinase results in the disruption of …
[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …